100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
Noah Rosen(Hofstra University), Abraham J. Nagy(Carolina Headache Institute), Kathleen A. Day(Eli Lilly (United States)), Eric Pearlman(University of California, San Francisco), Dustin Ruff(Eli Lilly (United States))
Cited by 35
Related Papers
Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia
|The Journal of Experimental Medicine|1997|532
N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis
|Nature Communications|2020|453
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP
|Nature Communications|2016|446